SAB Biotherapeutics Inc expected to post a loss of 96 cents a share - Earnings Preview

SAB Biotherapeutics

15/05/2024 14:30

* SAB Biotherapeutics Inc  SABS.OQ   SABS.O  is expected
to show a
fall in quarterly revenue when it reports  results on May 17
(estimated) for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for SAB Biotherapeutics Inc
is for
a loss of 96 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for SAB
Biotherapeutics Inc is $15.50​, above​ its last closing price
of $4.05. ​​​

This summary was machine generated May 15 at 13:30 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)